Amneal Pharmaceuticals launches 2nd NDA Bortezomib for injection3.5mg/1.4ml in US

Shilpa Medicare's marketing partner, Amneal Pharmaceuticals, has launched BORUZU™, (Bortezomib for injection3.5mg/1.4ml), a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration The product has already been granted permanent J-code by U.S. Centers for Medicare & Medicaid Services (CMS).

BORUZU (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma. This product references the branded product Velcade®, a lyophilized powder requiring reconstitution before use. Shilpa developed the molecule and Amneal will manufacture and commercialize the product.

"This is the second NDA product being launched in the US market from our novel injectable portfolio demonstrates our capabilities and commitment to introduce pharmacy efficient solutions that enhance compliance and have the potential to reduce patient wait times. This development exemplifies Shilpa's constant endeavor to work towards introducing novel first of its kind pharmaceutical products that help improve the healthcare requirements of a large patient pool," said Vishnukant Bhutada, Managing Director of Shilpa Medicare.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 648.20 as compared to the previous close of Rs. 657.90. The total number of shares traded during the day was 9312 in over 895 trades.

The stock hit an intraday high of Rs. 660.00 and intraday low of 645.60. The net turnover during the day was Rs. 6054430.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 Pharmaceuticals MarketingPartner AmnealPharmaceuticals BORUZU Bortezomib Injection